Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Foundation Fighting Blindness Stories

2010-07-22 01:49:05

UMass Medical School coordinating a $2.1 million three-year clinical trial Researchers at the University of Massachusetts Medical School (UMMS) believe they may have found a new treatment for retinitis pigmentosa (RP), a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young...

2010-06-14 13:01:08

Researchers working toward cure for pigmentosa; other retinal diseases Researchers at the University of Oklahoma Health Sciences Center have found a way to use a radical new type of gene therapy to prevent blindness caused by retinitis pigmentosa, giving hope to the estimated 100,000 Americans who suffer from this debilitating disease. The study appears in the Journal of the Federation of American Societies for Experimental Biology (FASEB). The research, led by Muna Naash, Ph.D., at the...

15a4a91e4d70473612e4fbc5b0312cd21
2010-04-29 10:42:56

Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration. In this study, the viral vector, or missile that carries the genetic material designed to correct a DNA mutation, was not intended to treat a disease but to demonstrate through the use of a fluorescent protein that a...

2010-04-21 14:47:00

PHILADELPHIA -- Veterinary ophthalmology researchers from the University of Pennsylvania have used gene therapy to restore retinal cone function and day vision in two canine models of congenital achromatopsia, also called rod monochromacy or total color blindness. Achromatopsia is a rare autosomal recessive disorder with an estimated prevalence in human beings of about 1 in 30,000 to 50,000. It primarily affects the function of the cone photoreceptors in the retina and serves as a...

2010-02-24 14:36:45

Findings could affect future treatments for macular degeneration, stargardt disease & other forms of retinal disease NEW YORK -- An international research team led by Columbia University Medical Center successfully used mouse embryonic stem cells to replace diseased retinal cells and restore sight in a mouse model of retinitis pigmentosa. This strategy could potentially become a new treatment for retinitis pigmentosa, a leading cause of blindness that affects approximately one in 3,000 to...

2009-10-24 13:00:00

PHILADELPHIA, Oct. 24 /PRNewswire/ -- Born with a retinal disease that made him legally blind, and would eventually leave him totally sightless, the nine-year-old boy used to sit in the back of the classroom, relying on the large print on an electronic screen and assisted by teacher aides. Now, after a single injection of genes that produce light-sensitive pigments in the back of his eye, he sits in front with classmates and participates in class without extra help. In the playground, he...

2009-10-20 19:16:21

Retinal prosthesis and fetal tissue transplant show promise in human studies Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind. Researchers also reported that an engineered protein restored...

2009-06-10 09:35:00

Walkers Raised $3000 to Help Fund Sight-Saving Research Through Foundation Fighting Blindness DALLAS, June 10 /PRNewswire/ -- Principal Management Group of North Texas (PMG), an Associa Company, recently participated in a walk-a-thon as "Bonnie Believers" in support of the Greater DFW Chapter of the Foundation Fighting Blindness, Inc. (FFB). The walk-a-thon is the 2nd annual for Dallas and is the signature fundraiser for Foundation Fighting Blindness, Inc. Over 350 participants joined in...

2009-05-28 07:32:00

LINCOLN, R.I., May 28 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. today announced that the Company's product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which...

2008-10-30 09:00:41

StemCells, Inc. (NASDAQ:STEM) reported today that its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells), when transplanted into a well-established animal model, can protect the retina from progressive degeneration. Retinal degeneration leads to loss of vision in diseases such as age-related macular degeneration and retinitis pigmentosa. This promising study was conducted by Dr. Raymond Lund, a researcher and professor at the Casey Eye Institute at Oregon Health...